<DOC>
	<DOCNO>NCT01998789</DOCNO>
	<brief_summary>The purpose study evaluate efficacy everolimus conversion ( EVR ) protocol compare standard tacrolimus ( TAC ) base protocol liver transplant recipient , determine renal function , rejection rate , progression fibrosis ( HCV positive subject ) . Additionally , safety profile tolerability regimens assess .</brief_summary>
	<brief_title>Everolimus Post Orthotopic Liver Transplant</brief_title>
	<detailed_description>The mainstay maintenance immunosuppression post-transplantation include calcineurin inhibitor , either cyclosporine tacrolimus . The introduction calcineurin inhibitor lead significant improvement graft patient outcomes post solid organ transplantation . However , one severe limitation class drug , associate nephrotoxicity . Data Scientific Registry Transplant Recipients reveal incidence stage 4 chronic kidney disease stage 5 Chronic Kidney Disease ( CKD ) Orthotopic Liver Transplantation ( OLT ) 1 , 3 , 5 year 8 % , 14 % , 18 % , respectively , increase approximately 25 % 10 year transplantation.Furthermore , renal dysfunction associate four-fold increase patient mortality post solid organ transplantation . Several calcineurin inhibitor spar minimize regimen study . Most recently , phase III , randomize study de novo liver transplant recipient , demonstrate significantly improve renal function tacrolimus minimization arm ( everolimus plus tacrolimus one year post transplant.In fact superior renal function achieve tacrolimus minimization arm one month randomization maintain Month 12 . With pilot study , aim compare efficacy standard immunosupression post liver transplant Tacrolimus Mycophenolic acid ( Myfortic ) calcineurin spar regimen use combination everolimus enteric coat mycophenolic acid , determine estimate Glomerular filtration rate ( GFR ) one year post transplant , acceptable rate biopsy proven rejection .</detailed_description>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Ability willingness provide inform consent adhere study regimen Recipients primary liver transplant decease live donor 18 year age great Lab Model For EndStage Liver Disease ( MELD ) score ≤ 30 Abbreviated Modification Diet Renal Disease ( MDRD ) eGFR ≥ 30 mL/min/1.73 Key Recipient multiple solid organ transplant , previously receive organ transplant Women childbearing potential unless willing participate adequate contraception method outline study . HIV infection ( result obtain 6 month prior screen acceptable ) Key ExclusionBaseline/ Randamization Severe hypercholesterolemia ( &gt; 350 mg/dL ) hypertriglyceridemia ( &gt; 500 mg/dL ) within 30 day prior baseline . Thrombocytopenia ( platelet &lt; 50,000/mm3 ) Absolute neutrophil count &lt; 1000/mm3 white blood cell count &lt; 2000/mm3 Subjects critical care unit require life support measure mechanical ventilation , dialysis , requirement vasopressor agent Liver allograft function unacceptable level define Aspartate Aminotransferase ( AST ) , Alanine Aminotransferase ( ALT ) , Total Bilirubin level &gt; 3 time upper limit normal ( ULN ) Alkaline Phosphatase ( AlkP ) Gammaglutamyltransferase ( GGT ) level &gt; 5 time ULN Diagnosis autoimmune hepatitis , primary biliary cirrhosis primary sclerosing cholangitis Hepatocellular carcinoma evidence macrovascular invasion explanted liver evidence extrahepatic spread Inability take medication mouth Renal insufficiency , define abbreviate MDRD eGFR &lt; 30 mL/min/1.73m2 , requirement dialysis , recover prior baseline Episode acute rejection require antibody therapy one steroid treat episode acute rejection Subjects confirm spot urine protein/creatinine ratio indicate ≥1g/24h proteinuria . Subtherapeutic trough level tacrolimus week prior baseline ( subject must least one tacrolimus level ≥ 8 ng/mL ) The presence thrombosis via Doppler ultrasound major hepatic artery , major hepatic vein , portal vein inferior vena cava . Presence clinically significant wound</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Liver Transplantation</keyword>
	<keyword>Everolimus</keyword>
	<keyword>Immunosuppression</keyword>
</DOC>